类风湿关节炎停用TNF抑制剂后的治疗序列:循环与转换策略比较
基于Truven Health MarketScan数据库分析10,442例RA患者,初始TNFi失败后63.5%循环至第二种TNFi,36.5%转换至非TNFi。转换至非TNFi者停药时间更长(中位605天 vs 489天,P<0.001),但循环至TNFi总体费用更低。
要点
- 初始TNFi失败后多数患者(63.5%)选择循环至第二种TNFi,36.5%转换至非TNFi。
- 转换至非TNFi者停药时间更长(中位605天 vs 489天,P<0.001)。
- 循环至TNFi策略总体费用更低。
核心结论
- 尽管患者更可能循环至第二种TNFi而非转换至非TNFi,但转换至非TNFi者治疗持续性更好,而循环至TNFi费用更低。
主要发现
- 共识别10,442例RA患者,36.5%转换至非TNFi(最常用阿巴西普54.2%),63.5%循环至第二种TNFi(最常用阿达木单抗41.2%)。
- 转换至非TNFi者年龄更大、合并症更多(P<0.001)。
- 初始TNFi停药后,非TNFi停药时间中位605天,TNFi中位489天(P<0.001);后续切换无差异。
- 非TNFi对依从患者费用更低,但循环至TNFi总体费用更低。
临床怎么用
- 初始TNFi失败后选择循环TNFi或转换非TNFi需权衡治疗持续性与费用。
- 转换至非TNFi可能延长治疗持续性,但总体费用更高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the sequences of tumor necrosis factor inhibitors (TNFi) and non-TNFi used by rheumatoid arthritis (RA) patients whose initial TNFi therapy has failed, and to evaluate effectiveness and costs. METHODS: Using the Truven Health MarketScan Research database, we analyzed claims of commercially insured adult patients with RA who switched to their second biologic or targeted disease-modifying antirheumatic drug between January 2008 and December 2015. Our primary outcome was the frequency of treatment sequences. Our secondary outcomes were the time to therapy discontinuation, drug adherence, and drug and other health care costs. RESULTS: Among 10,442 RA patients identified, 36.5% swapped to a non-TNFi drug, most commonly abatacept (54.2%). The remaining 63.5% cycled to a second TNFi, most commonly adalimumab (41.2%). For subsequent switches of therapy, non-TNFi were more common. Patients who swapped to a non-TNFi were significantly older and had more comorbidities than those who cycled to a TNFi (P < 0.001). Survival analysis showed a longer time to discontinuation for non-TNFi than for TNFi (median 605 days compared with 489 days; P < 0.001) when used after initial TNFi discontinuation, but no difference in subsequent switches of therapy. Although non-TNFi were less expensive for adherent patients, cycling to a TNFi was associated with lower costs overall. CONCLUSION: Even though patients are more likely to cycle to a second TNFi than swap to a non-TNFi, those who swap to a non-TNFi are more likely to persist with the therapy. However, cycling to a TNFi is the less costly strategy.
引用
- Karpes Matusevich AR, Duan Z, Zhao H, et al. Treatment Sequences After Discontinuing a Tumor Necrosis Factor Inhibitor in Patients With Rheumatoid Arthritis: A Comparison of Cycling Versus Swapping Strategies. Arthritis Care Res (Hoboken). 2021. PMID: 32558339. doi:10.1002/acr.24358
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。